ALNA - Allena Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.0000
-0.0100 (-0.20%)
As of 9:39AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.0100
Open5.1600
Bid4.2000 x 1100
Ask0.0000 x 1000
Day's Range5.0000 - 5.1550
52 Week Range3.3300 - 10.6600
Volume3,311
Avg. Volume74,946
Market Cap117.328M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.0090
Earnings DateAug 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.86
Trade prices are not sourced from all markets
  • GlobeNewswire

    Allena Pharmaceuticals to Present New Data on Reloxaliase and ALLN-346 Development Programs at Upcoming ASN Kidney Week and ACR/ARP Annual Meeting

    NEWTON, Mass., Oct. 17, 2019 -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,.

  • Allena Pharmaceuticals, Inc. (ALNA) Upgraded to Buy: Here's Why
    Zacks

    Allena Pharmaceuticals, Inc. (ALNA) Upgraded to Buy: Here's Why

    Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • GlobeNewswire

    Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has completed enrollment in its pivotal Phase 3 URIROX-1 clinical trial. URIROX-1 is a multi-center, global, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of reloxaliase for the treatment of patients with enteric hyperoxaluria.

  • GlobeNewswire

    Allena Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Enteric Hyperoxaluria and Potential for Reloxaliase

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it will host a key opinion leader symposium on the unmet need in enteric hyperoxaluria and the potential for reloxaliase as a first-in-class therapy for patients. Scheduled to speak at the event is Gregory Tasian, M.D., Assistant Professor of Urology in Surgery and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania and Attending Pediatric Urologist at the Children’s Hospital of Philadelphia (CHOP). Additionally, Allena management will provide an overview of the market opportunity in enteric hyperoxaluria and its ongoing clinical development programs for reloxaliase, with a focus on URIROX-1, its first pivotal Phase 3 trial.

  • GlobeNewswire

    Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September

    NEWTON, Mass., Aug. 29, 2019 -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,.

  • GlobeNewswire

    Allena Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the second quarter ended June 30, 2019 and also provided a business update. “At Allena, we are committed to providing a first-in-class treatment for the full spectrum of patients with enteric hyperoxaluria (EH),” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “The initial data from Study 206 represent meaningful progress toward achieving this vision, as we showed for the first time reloxaliase’s ability to reduce both urine and plasma oxalate in patients with EH and impaired kidney function, including patients with advanced chronic kidney disease, dialysis-dependence, and transplantation.

  • GlobeNewswire

    Allena Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference

    NEWTON, Mass., Aug. 06, 2019 -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,.

  • Can All-Line Growth Aid CVS Health's (CVS) Earnings in Q2?
    Zacks

    Can All-Line Growth Aid CVS Health's (CVS) Earnings in Q2?

    Within the Health Care Benefits segment, CVS Health (CVS) expects the government programs to go from strength to strength on the back of Medicare growth and major Medicaid wins.

  • Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store?
    Zacks

    Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store?

    Henry Schein (HSIC) is working diligently to grow in the field of digital dentistry, globally.

  • Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
    Zacks

    Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?

    Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.

  • What's in the Cards for DaVita (DVA) This Earnings Season?
    Zacks

    What's in the Cards for DaVita (DVA) This Earnings Season?

    DaVita (DVA) projects operating income within $460-$465 million for the second quarter.

  • What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
    Zacks

    What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

    Better-than-expected performance at Technology & Equipment and growth in emerging markets are likely to aid DENTSPLY SIRONA (XRAY) in Q2 earnings.

  • AmerisourceBergen (ABC) Q3 Earnings: What's in the Offing?
    Zacks

    AmerisourceBergen (ABC) Q3 Earnings: What's in the Offing?

    Better-than-expected performance at Pharmaceutical Distribution and higher revenues are likely to aid AmerisourceBergen (ABC) in Q3 earnings.

  • Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?
    Zacks

    Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?

    ABIOMED's (ABMD) flagship Impella receives a slew of regulatory approvals.

  • Masimo (MASI) to Report Q2 Earnings: What's in the Offing?
    Zacks

    Masimo (MASI) to Report Q2 Earnings: What's in the Offing?

    Masimo's (MASI) recent developments likely to show on second-quarter results.

  • What's in the Offing for DexCom's (DXCM) Earnings in Q2?
    Zacks

    What's in the Offing for DexCom's (DXCM) Earnings in Q2?

    Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.

  • GlobeNewswire

    Allena Pharmaceuticals Announces $10.0 Million Registered Direct Offering of Common Stock

    Allena intends to use the net proceeds to fund its clinical development programs and for working capital and other general corporate purposes, including the advancement of its lead candidate reloxaliase, an orally-administered, recombinant oxalate-degrading enzyme that is being developed for the treatment of enteric hyperoxaluria. The securities described above are being offered pursuant to Allena’s shelf registration statement on Form S-3 (File No. 333-228656) filed with the Securities and Exchange Commission (SEC), which was declared effective on December 26, 2018.  A prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.  Copies of such prospectus supplement and accompanying base prospectus may also be obtained directly from Allena by contacting Allena Pharmaceuticals, Inc., Attn: Investor Relations, One Newton Executive Park, Suite 202, Newton, Massachusetts, 02462, or by telephone at 617-467-4577.

  • GlobeNewswire

    Allena Pharmaceuticals Showcases Reloxaliase and Enteric Hyperoxaluria Program at OHF International Hyperoxaluria Workshop

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it will present on its reloxaliase development program and the unmet need in patients with enteric hyperoxaluria (EH) in four sessions at the Oxalosis & Hyperoxaluria Foundation (OHF) International Hyperoxaluria Workshop, to be held June 21-22, 2019 in Boston, MA.  The OHF International Hyperoxaluria Workshop is the largest gathering of hyperoxaluria patients, disease advocates and thought leaders worldwide. “Allena’s strong presence at the OHF International Hyperoxaluria Workshop highlights our progress in developing reloxaliase as a potential first-in-class therapy for patients suffering from enteric hyperoxaluria, as well as our ongoing efforts to work with advocacy groups and treating physicians to better characterize the progression of this debilitating disease,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals.

  • Benzinga

    The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

    For biotech stocks, the week was back loaded with multiple conferences scheduled for the later half of the week. Nevertheless, there were volatile moves in some low-float, thinly traded stocks. Looking ...

  • GlobeNewswire

    Allena Pharmaceuticals Announces Interim Results from Study 206 of Reloxaliase in High Risk Patients with Advanced Oxalate Disorders

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced interim data from Study 206, its Phase 2 basket clinical trial of reloxaliase, an orally-administered, recombinant oxalate-degrading enzyme. Study 206 includes adult and pediatric patients suffering from the progression of primary hyperoxaluria (PH) or enteric hyperoxaluria (EH) with advanced chronic kidney disease (CKD), both of which can lead to systemic oxalosis, a potentially life-threating condition.

  • GlobeNewswire

    Allena Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will present a corporate overview at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 8:00 a.m. ET in New York, NY. A live audio webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com.

  • All You Need to Know About Allena Pharmaceuticals, Inc. (ALNA) Rating Upgrade to Buy
    Zacks

    All You Need to Know About Allena Pharmaceuticals, Inc. (ALNA) Rating Upgrade to Buy

    Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • GlobeNewswire

    Allena Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the first quarter ended March 31, 2019 and also provided a business update. “Our progress in the first quarter highlights our position as pioneers in the development of oral enzyme therapeutics for the treatment of rare and severe metabolic diseases,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “We achieved alignment with the U.S. Food and Drug Administration (FDA) on the design of URIROX-2 and on our strategy to pursue an accelerated approval for reloxaliase in patients with enteric hyperoxaluria.  We are continuing to enroll our ongoing clinical trials, with a focus on completing enrollment in URIROX-1.

  • Investors Who Bought Allena Pharmaceuticals (NASDAQ:ALNA) Shares A Year Ago Are Now Down 52%
    Simply Wall St.

    Investors Who Bought Allena Pharmaceuticals (NASDAQ:ALNA) Shares A Year Ago Are Now Down 52%

    Taking the occasional loss comes part and parcel with investing on the stock market. And unfortunately for Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) shareholders, the stock is a lot lower today than it was a year ago. The sh...

  • GlobeNewswire

    Allena Pharmaceuticals Appoints Allene Diaz to its Board of Directors

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Allene Diaz to its Board of Directors. “We are pleased to welcome Allene to our Board of Directors,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “Allene joins our team at an opportune time, as we advance our ongoing Phase 3 URIROX™ program and make progress in our quest to deliver the first therapeutic for patients with enteric hyperoxaluria.